BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Feb 9, 2018
Clinical News

Eisai, Meiji Seika's safinamide meets in Phase II/III for PD

Eisai Co. Ltd. (Tokyo:4523) and Meiji Seika Pharma Co. Ltd. (Tokyo, Japan) reported preliminary data from a Phase II/III trial in about 410 Parkinson's disease patients with wearing-off phenomenon showing that once-daily 50 and 100...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BC Week In Review | Mar 23, 2017
Clinical News

Xadago regulatory update

FDA approved an NDA for Xadago safinamide from Newron as an add-on treatment for patients with Parkinson's disease (PD) who are currently taking levodopa/carbidopa and experiencing "off" episodes. In March 2016, FDA issued a complete...
BC Extra | Mar 21, 2017
Company News

FDA approves Newron's Xadago

FDA approved Xadago safinamide from Newron Pharmaceuticals S.p.A. (SIX:NWRN) as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and experiencing "off" episodes. In March 2016, FDA issued a complete response...
BC Week In Review | Jan 20, 2017
Company News

Zambon, CSL deal

Zambon granted CSL’s Seqirus unit exclusive rights to develop and commercialize Parkinson’s disease drug Xadago safinamide in Australia and New Zealand. Zambon has exclusive rights from Newron Pharmaceuticals S.p.A. (SIX:NWRN, Bresso, Italy) to develop and...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BioCentury | Dec 16, 2016
Regulation

Blip or dip?

In a ritual held each year a couple of weeks before the winter solstice, pundits pore over FDA’s new drug approval statistics and use them to pontificate about the health of the biopharma industry and...
BC Week In Review | Oct 31, 2016
Clinical News

Xadago safinamide regulatory update

Newron said FDA accepted a resubmitted NDA for Xadago safinamide from Newron as an add-on therapy for early and mid- to late-stage Parkinson’s disease (PD). The PDUFA date is March 21, 2017. In March, FDA...
Items per page:
1 - 10 of 118